EGF and breast carcinoma: In summary, both breast cancer cell lines (MDA-MB-231 and MCF10CA1a) exhibited a directional response with EGF(−)/iEF(+) treatment by migrating faster and with greater persistence with iEFs applied in the antiparallel direction when compared with untreated controls.